COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bioavailability Study of Tramadol/APAP Tablets Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00653315
Recruitment Status : Completed
First Posted : April 4, 2008
Last Update Posted : April 11, 2008
AAI Clinic
Information provided by:
Par Pharmaceutical, Inc.

Brief Summary:
To compare the relative bioavailability of Kali and Ortho-McNeil's

Condition or disease Intervention/treatment Phase
To Determine Bioequivalence Under Fasting Conditions Drug: Tramadol APAP Drug: Ultracet Phase 1

Detailed Description:
To compare the relative bioavailability of Kali's Tramadol/APAP 37.5mg/325mg with Ortho-McNeil's Ultracet tablets 37.5mg/325mg

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fasting Conditions.
Study Start Date : May 2002
Actual Primary Completion Date : August 2002
Actual Study Completion Date : August 2002

Resource links provided by the National Library of Medicine

Drug Information available for: Tramadol

Arm Intervention/treatment
Experimental: A
Subjects received kali product under fasting conditions
Drug: Tramadol APAP
Tablets, 37.5mg/325mg, single dose
Other Name: Ultracet

Active Comparator: B
Subjects received Ortho-Mcneil product under fasting conditions
Drug: Ultracet
Tablets, 37.5mg/325mg
Other Name: Tramadol APAP

Primary Outcome Measures :
  1. Rate and Extend of absorption [ Time Frame: 24 Hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy Males and females between 18 and 45 years of age inclusive
  • Informed of the nature of the study and given written informed consent.
  • Have a body weight within 15% of the appropriate range as defined in the 1983 Metropolitan Life Company tables and weighing at least 100lbs.

Exclusion Criteria:

  • Hypersensitivity to Tramadol/ Acetaminophen, opioids such as morphine and codeine, or related compounds, or a history or seizures.
  • Any history of a clinical condition which might affect drug absorption, metabolism or excretion.
  • Recent history (within one year) of mental illness, drug illness, drug abuse or alcoholism.
  • Donation of greater than 500mL of blood in the past 4 weeks prior to study dosing or difficulty in donating blood.
  • Received an investigational drug within the 4 weeks prior to study dosing.
  • Currently taking any prescription medication, except oral contraceptives, within 7days prior to study dosing or over-the-counter medication within 3 days of the study dosing.
  • This prohibition does not include vitamins or herbal preparations taken as nutritional supplements for non-therapeutic indications as judged by the physician.
  • Tobacco use(>5 cigarettes per day)in the 3 months prior to study dosing.
  • If female, the subject is lactating or has a positive pregnancy test at screening and prior to each of the two treatment periods.
  • Females of child bearing potential must use a medically acceptable method of contraception throughout the entire study period and for one week after the study is completed.
  • Medically acceptable methods of contraception that may be used by the subject and/or her partner are:oral contraceptive, progestin injection or implants, condom with spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization of their partner(s) or abstinence.
  • females taking oral contraceptives must have taken them consistently for at least three months prior to receiving study medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00653315

Sponsors and Collaborators
Par Pharmaceutical, Inc.
AAI Clinic
Layout table for investigator information
Principal Investigator: Ralph Scallion AAI Clinic
Layout table for additonal information
Responsible Party: Alfred Elvin// Director Biopharmaceutics, Par Pharmaceutical, Inc. Identifier: NCT00653315    
Other Study ID Numbers: AAI-US-121
First Posted: April 4, 2008    Key Record Dates
Last Update Posted: April 11, 2008
Last Verified: April 2008
Keywords provided by Par Pharmaceutical, Inc.:
Bioequivalence, Tramadol APAP, fasting
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents